tradingkey.logo

Mirum Pharmaceuticals Says Health Canada Authorizes Livmarli For Cholestatic Pruritus In Progressive Familial Intrahepatic Cholestasis (Pfic) Patients

ReutersFeb 5, 2026 1:20 PM

- Mirum Pharmaceuticals Inc MIRM.O:

  • MIRUM PHARMACEUTICALS ANNOUNCES HEALTH CANADA AUTHORIZATION OF LIVMARLI® FOR THE TREATMENT OF CHOLESTATIC PRURITUS IN PATIENTS WITH PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS (PFIC)

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI